Avidity Biosciences, Inc. - Common Stock (RNA)

Avidity's del-zota met key Phase 1/2 trial goals in DMD44, shows strong exon skipping, dystrophin restoration and creatine kinase reduction.

On Tuesday, BMO Capital Markets initiated coverage on Dyne Therapeutics, Inc. (NASDAQ:DYN), focused on developing therapies for ...

William Blair starts coverage on Denali Therapeutics with an Outperform rating, citing its transport vehicle platform and promising therapies for neurodegenerative diseases.

The company is now pivoting its technology to the cardiovascular space under a partnership with Bristol Myers Squibb.

The company is working on treatments for forms of muscular dystrophy, and is taking on some of the biggest names in pharma.

The company's most promising pipeline program can continue unabated.

Goldman Sachs has initiated coverage on Avidity Biosciences with a Buy rating and a $59 price target, citing multi-blockbuster commercial opportunities for its RNA therapeutics in muscular dystrophies.

BofA Securities upgraded Fulcrum Therapeutics ahead of its phase 3 losmapimod results for Facioscapulohumeral muscular dystrophy, boosting the price target from $5 to $10 due to increased confidence in the study's success.

RNA stock results show that Avidity Biosciences beat analyst estimates for earnings per share but missed on revenue for the second quarter of 2024.

The company is coming up fast with a platform that could take on several of Sarepta's approved treatments.

These three stellar, outperforming stocks are doing better than even Super Micro Computer, which has been running away from the market.